Thermo Fisher Scientific One Lambda Pre-Transplant Risk Assessment (PTRA) Assay
Thermo Fisher Scientific has launched the One Lambda Pre-Transplant Risk Assessment (PTRA) assay, a pre-transplant risk assessment assay that helps assess the risk of early acute rejection in kidney transplant recipients. The assay was developed and validated by the CLIA-certified Thermo Fisher One Lambda Laboratories and is used clinically as a laboratory-developed test. According to Thermo Fisher, the PTRA assay utilizes 29 mRNA markers to help stratify patients into high- and low-risk categories for early acute rejection. A recent clinical validation study observed that patients with high PTRA scores were six times more likely to experience early acute rejection than patients with low-risk scores, the company said.